Breast Cancer

, 3:93 | Cite as

Immunohistochemical study of cell cycle modulators in G1-S transition in clinical breast cancer tissue

  • Yasuhiro Ito
  • Tetsuro Kobayashi
  • Tsutomu Takeda
  • Yoshifumi Komoike
  • Eijiro Wakasugi
  • Yasuhiro Tamaki
  • Koji Umeshita
  • Takushi Monden
  • Morito Monden
Original Article
Received:
Accepted:

Abstract

In the present study, we investigated immunolocalization of the modulators of G1-S transition by using monoclonal or polyclonal antibodies for each of the modulators in 65 cases of clinical breast cancer. Two prominent cyclin dependent kinase (cdk)-cyclin complexes, cdk4-cyclin D and cdk2-cyclin E, were proved to have different modes of mutual expression. cdk4-positive lesions were found to equal cyclin D-expressing lesions in 55 cases, while the former were more extensive than the latter in 9 cases. On the other hand, cyclin E expression was detected in all the cases examined and was more dominant than that of cdk2/cdc2 in as many as 40 cases whereas the reverse was seen in only 1 case. Interestingly, cdk4 (p<0.01) and cyclin E (p<0.05) expressions showed an inverse relationship with the tumor size and the cancer stage. A similar tendency was also detected for two other positive modulators of G1-S transition, indicating that cell cycle progression must be regulated by the cancer itself once it has grown to a certain extent. p21, which has been regarded as a universal inhibitor of the cell cycle, was expressed in 43.1% of the cases examined and its immunoreactivity showed an inverse relationship with lymph node metastasis (p<0.05). It also tended to be absent more frequently in T3 or larger cancers and stage III cases. Moreover, two patients who died as a result of cancer and three patients with recurrence were all p21 negative, suggesting that p21 is prognosticably the most significant of all these modulators.

Key words

cdk G1 cyclins Breast cancer p21 Immunohistochemistry 

Abbreviations

cdk

Cyclin dependent kinase

PBS

Phosphate buffered saline (pH 7.2)

This is a preview of subscription content, log in to check access.

References

  1. 1).
    Huang HJ, Yee JK, Shew JY,et al: Suppression of the neoplastic phenotype by replacement of the retinoblastoma gene product in human cancer cells.Science 242:1563–1566, 1988.PubMedCrossRefGoogle Scholar
  2. 2).
    Friend SH, Bernards R, Rogelj S: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.Nature 323:643- 646, 1986.PubMedCrossRefGoogle Scholar
  3. 3).
    Harbour JW, Lai SL, Whang-Peng J,et al: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.Science 241:353–357, 1988.PubMedCrossRefGoogle Scholar
  4. 4).
    Horowitz JM, Yandell DW, Park SH,et al: Point mutational inactivation of the retinoblastoma antioncogene.Science 243:937–940, 1989.PubMedCrossRefGoogle Scholar
  5. 5).
    Murphree AL, Benedict WF: Retinoblastoma; Clues to human oncogene.Science 223:1028–1033, 1984.PubMedCrossRefGoogle Scholar
  6. 6).
    Gope R, Christensen MA, Thorson A,et al: Increased expression of retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa.J Natl Cancer Inst 82:310–314, 1990.PubMedCrossRefGoogle Scholar
  7. 7).
    Lee WH, Bookstain R, Hong F,et al: Human retinoblastoma susceptibility gene; Cloning, identification and sequence.Science 235:1394–1399, 1987.PubMedCrossRefGoogle Scholar
  8. 8).
    Goodrich DW, Wang NP, Qian YW,et al: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle.Cell 67:293–302, 1991.PubMedCrossRefGoogle Scholar
  9. 9).
    Sawan A, Randall B, Angus B,et al: Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer; An immunohistochemical study.J Pathol 168:23–28, 1992.PubMedCrossRefGoogle Scholar
  10. 10).
    Spandidos DA, Karaiossifidi H, Malliri A,et al: Expression of ras, Rb1 and p53 proteins in human breast cancer.Anticancer Res 12:81–89, 1992.PubMedGoogle Scholar
  11. 11).
    Trudel M, Mulligan L, Cavenee W,et al: Retinoblastoma and p53 gene product expression in breast carcinoma; Immunohistochemical analysis and clinicopathologic correlation.Human Pathol 23:1388–1394, 1992.CrossRefGoogle Scholar
  12. 12).
    Fukuda K, Monden T, Yamamoto H,et al: Immunohistochemical study of retinoblastoma gene expression in colorectal carcinomas.Int J Oncol 4:117–121, 1994.Google Scholar
  13. 13).
    Higashiyama M, Doi O, Kodama K,et al: Retinoblastoma protein expression in lung cancer; An immunohistocemical analysis.Oncology 51:544–551, 1994.PubMedGoogle Scholar
  14. 14).
    Xu HJ, Quinlan DC, Davidson AG,et al: Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.J Natl Cancer Inst 86:695–699, 1994.PubMedCrossRefGoogle Scholar
  15. 15).
    Cordon-Cardo C, Wartinger D, Petrylak D,et al: Altered expression of the retinoblastoma gene product; Prognostic indicator in bladder cancer.J Natl Cancer Inst 84:1251–1256, 1992.PubMedCrossRefGoogle Scholar
  16. 16).
    Goodrich DW, Chen Y, Scully P,et al: Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation.Cancer Res 52:1968–1973, 1992.PubMedGoogle Scholar
  17. 17).
    Constancia M, Seruca R, Carneiro F,et al: Retinoblastoma gene structure and product expression in human gastric carcinomas.Br J Cancer 70:1018–1024, 1994.PubMedGoogle Scholar
  18. 18).
    Mihara K, Cao XR, Yen A,et al: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product.Science 246:1300–1303, 1989.PubMedCrossRefGoogle Scholar
  19. 19).
    Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle.Cell 58:1097–1105, 1989.PubMedCrossRefGoogle Scholar
  20. 20).
    Meyerson M, Enders GH, Wu C-L,et al: A family of human cdc2-related protein kinases.EMBO J 11:2909- 2917, 1992.PubMedGoogle Scholar
  21. 21).
    Sherr CJ: Mammalian G1 cyclins.Cell 73:1059–1065, 1993.PubMedCrossRefGoogle Scholar
  22. 22).
    Akiyama T, Ohuchi T, Sumida S,et al: Phosphorylation of the retinoblastoma protein by cdk2.Proc Natl Acad Sci USA 89:7900–7904, 1992.PubMedCrossRefGoogle Scholar
  23. 23).
    Kato J, Matsushime H, Hiebert SW,et al: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by cyclin D dependent kinase CDK4.Genes Dev 7:331–342, 1993.PubMedCrossRefGoogle Scholar
  24. 24).
    Matsushime H, Roussel MF, Sherr CJ: Novel mammalian cyclin (CYL) genes expressed during G1.Cold Spring Harbor Symp Quant Biol 56:69–74, 1991.PubMedGoogle Scholar
  25. 26).
    Matsushime H, Roussel MF, Ashmun RA,et al: Colony-stimulating factor 1 regulates novel cyclins during the G1 phases of the cell cycle.Cell 65:701–713, 1991.PubMedCrossRefGoogle Scholar
  26. 27).
    Matsushime H, Ewen ME, Strom DK,et al: Identification and properties of an atypical catalytic subunit (p34PSKJ3/cdk4) for mammalian D type G1 cyclins.Cell 71:323–334, 1992.PubMedCrossRefGoogle Scholar
  27. 28).
    Koff A, Cross F, Fisher A,et al: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.Cell 66:1217–1228, 1991.PubMedCrossRefGoogle Scholar
  28. 29).
    Koff A, Giordano A, Desai D,et al: Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.Science 257:1689–1694, 1992.PubMedCrossRefGoogle Scholar
  29. 30).
    Fantl V, Smith R, Brookes S,et al: Chromosome 11q13 abnormalities in human breast cancer.Cancer Surv 18:77–94, 1993.PubMedGoogle Scholar
  30. 31).
    Buckley MF, Sweeney KJE, Hamilton JA,et al: Expression and amplification of cyclin genes in human breast cancer.Oncogene 8:2127–2133, 1993.PubMedGoogle Scholar
  31. 32).
    Motokura T, Arnold A: Cyclins and oncogenesis.Biochim Biophys Acta 1155:63–78, 1993.PubMedGoogle Scholar
  32. 33).
    Jiang W, Zhang Y-J, Kahn SM,et al: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer.Proc Natl Acad Sci USA 90:9026–9030, 1993.PubMedCrossRefGoogle Scholar
  33. 34).
    Zhang Y-J, Jiang W, Chen CJ,et al: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma.Biochem Biophys Res Commun 196: 1010–1016, 1993.PubMedCrossRefGoogle Scholar
  34. 35).
    Bartkova J, Lukas J, Strauss M,et al: The PRAD-1/ Cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas.Int J Cancer 58: 568–573, 1994.PubMedCrossRefGoogle Scholar
  35. 36).
    Bartkova J, Lukas J, Muller H,et al: Cyclin D1 protein expression and function in human breast cancer.Int J Cancer 57:353–361, 1994.PubMedCrossRefGoogle Scholar
  36. 37).
    Keyomarsi K, Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells.Proc Natl Acad Sci USA 90:1112–1116, 1993.PubMedCrossRefGoogle Scholar
  37. 38).
    Keyomarsi K, OLeary N, Molnar G,et al: Cyclin E, a potential prognostic marker for breast cancer.Cancer Res 54:380–395, 1994.PubMedGoogle Scholar
  38. 39).
    Serrano M, Hannon G, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.Nature 366:704–707, 1993.PubMedCrossRefGoogle Scholar
  39. 40).
    Xiong Y, Hannon GJ, Zhang H,et al: p21 is a universal inhibitor of cyclin kinases.Nature 366:701–704, 1993.PubMedCrossRefGoogle Scholar
  40. 41).
    Kamb A, Gruis NA, Weaver-Feldhaus J,et al: A cell cycle regulator potentially involved ingenesis of many tumor types.Science 264:436–439, 1994.PubMedCrossRefGoogle Scholar
  41. 42).
    El-Deiry WS, Tokino T, Velculescu VE,et al:WAF1, a potential mediator of p53 tumor suppression.Cell 75:817–825, 1993.PubMedCrossRefGoogle Scholar
  42. 43).
    Harper JW, Adami GR, Wei N,et al: The p21 Cdk- interacting protein Cipi1 is a potent inhibitor of G1 cyclin-dependent kinases.Cell 75:805–816, 1993.PubMedCrossRefGoogle Scholar
  43. 44).
    El-Deiry WS, Harper JW, O’Connor PM,et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.Cancer Res 54:1169–1174, 1994.PubMedGoogle Scholar
  44. 45).
    Yamamoto H, Monden T, Ikeda K,et al: Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer.Br J Cancer 71:1231–1236, 1995.PubMedGoogle Scholar
  45. 46).
    UICC: TNM Classification of Malignant Tumors, 4th ed, Springer-Verlag, New York, 1987.Google Scholar
  46. 47).
    Mathews MB, Bernstein RM, Franza BR,et al: Identity of the proliferating cell nuclear antigen and cyclin.Nature 303:374–376, 1984.CrossRefGoogle Scholar
  47. 48).
    Gerdes J, Lemke H, Baisch H,et al: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki67.J Immunol 133:1710–1716, 1984.PubMedGoogle Scholar
  48. 49).
    Coltrera MD, Gown AM: PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines.J Histochem Cytochem 39:23–30, 1991.PubMedGoogle Scholar
  49. 50).
    Woods AL, Hall PA, Stepherd NA,et al: The assessment of proliferating cell nuclear antigen (PCNA) imunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis.Histopathology 19:21–27, 1991.PubMedCrossRefGoogle Scholar
  50. 51).
    Hall PA, Levison DA, Woods AL,et al: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections; An index of cell proliferation with evidence of deregulated expression in some neoplasms.J Pathol 162:285–294, 1990.PubMedCrossRefGoogle Scholar
  51. 52).
    Celis JE, Celis A: Cell cycle dependent variations in the distribution of the nuclear protein cyclin/proliferating cell nuclear antigen in cultured cells; Subdivision of the S-phase.Proc Natl Acad Sci USA 82:3262- 3266, 1985.PubMedCrossRefGoogle Scholar
  52. 53).
    Haneda H, Katabami M, Miyamoto H,et al: The relationship of the proliferating cell nuclear antigen protein to CDDP resistance of a murine leukemia cell line P338/CDDP.Oncology 48:234–238, 1991.PubMedCrossRefGoogle Scholar
  53. 54).
    Kamel OW, Le Brun DP, Davis RE,et al: Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti- PCNA/cyclin 19A2.Am J Pathol 138:1471–1477, 1991.PubMedGoogle Scholar
  54. 55).
    Cummings MC, Furnival CN, Persons PG,et al: PCNA immunostaining in breast cancer.Aust NZ J Surg 63:630–636, 1993.CrossRefGoogle Scholar
  55. 56).
    Thomas M, Noguchi M, Kitagawa H,et al: Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma.J Clin Pathol 46: 525–528, 1993.PubMedCrossRefGoogle Scholar
  56. 57).
    Aaltomaa S, Lipponen P, Syrjanen K: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer.Anticancer Res 13:533–538, 1993.PubMedGoogle Scholar
  57. 58).
    Narita T, Funahashi H, Satoh Y,et al: Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.Jpn J Clin Oncol 23:20- 25, 1993.PubMedGoogle Scholar
  58. 59).
    Gasparini G, Meli S, Pozza F,et al: PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma.Growth Regul 2:145–150, 1992.PubMedGoogle Scholar
  59. 60).
    Pavelic ZP, Pavelic L, Lower EE,et al: c-myc, c-erbB- 2 and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.Cancer Res 52:2597–2602, 1992.PubMedGoogle Scholar
  60. 61).
    Bailo M, Nordling S, von-Boguslawsky K,et al: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer.Br J Cancer 68:579–583, 1993.Google Scholar
  61. 62).
    Carriero MV, Bevilacqua AM, Borrelli A,et al: Ki-67 and B72.3 expression in breast cancer; An immunohistochemical study.Int J Rad Appl Instrum B 18:95–99, 1991.PubMedGoogle Scholar
  62. 63).
    Rudas M, Gnant MF, Mittlbock M,et al: Thymidine labeling index and Ki-67 growth fraction in breast cancer; Comparison and correlation with prognosis.Breast Cancer Res Treat 32:165–175, 1994.PubMedCrossRefGoogle Scholar
  63. 64).
    Niezabitowski A, Lackowaska B, Rus J,et al: Flow cytometric evaluation of Ki67 proliferative antigen in primary breast cancer.Pol J Pathol 46:17–22, 1995.PubMedGoogle Scholar
  64. 65).
    Lees JA, Buchkovich KJ, Marshak DR,et al: The retinoblastoma protein is phosphorylated on multiple sites by human cdc2.EMBO J 10:4279–4290, 1991.PubMedGoogle Scholar
  65. 66).
    Lin BT-Y, Gruenwald S, Morla AO,et al: Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.EMBO J 10:857- 864, 1991.PubMedGoogle Scholar
  66. 67).
    El-Deiry WS, Tokino T, Waldman T,et al: Topological control of p21WAF1/DIP1 expression in normal and neoplastic tissues.Cancer Res 55:2910–2919, 1995.PubMedGoogle Scholar
  67. 68).
    Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer.Br J Cancer 11:359–377, 1957.PubMedGoogle Scholar
  68. 69).
    Sheikh MS, Li X-S, Cheo J-C,et al: Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma; Role of p53-dependent and independent signal trunsduction pathways.Oncogene 9:3407- 3415, 1994.PubMedGoogle Scholar
  69. 70).
    Michieli P, Chedid M, Lin D,et al: Induction of WAF1/CIP1 by a p53-independent pathway.Cancer Res 54f:3391–3395, 1994.Google Scholar
  70. 71).
    Zhang W, Grasso L, McClain CD,et al: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation.Cancer Res 55:668–674, 1995.PubMedGoogle Scholar
  71. 72).
    Jiang H, Lin J, Su Z-Z,et al: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expressioin in the absence of p53.Oncogene 9:3397–3406, 1994.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1996

Authors and Affiliations

  • Yasuhiro Ito
    • 1
  • Tetsuro Kobayashi
    • 2
  • Tsutomu Takeda
    • 1
  • Yoshifumi Komoike
    • 1
  • Eijiro Wakasugi
    • 1
  • Yasuhiro Tamaki
    • 1
  • Koji Umeshita
    • 1
  • Takushi Monden
    • 1
  • Morito Monden
    • 1
  1. 1.Department of Surgery IIOsaka University Medical SchoolSuitaJapan
  2. 2.Department of SurgeryOsaka National HospitalSuitaJapan

Personalised recommendations